Atriva Therapeutics' CEO on how this biopharma company tackles RNA viruses

Описание: Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19.
The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness.

The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses.

We spoke with founder and CEO, Rainer Lichtenberger at BIO-Europe. Lichtenberger is set to retire in 2023, and his successor has been announced as Christian Pangratz.

➡ Subscribe to our newsletter: https://bit.ly/3kHyfKc
➡ Get more biotech news:
Official site: https://bit.ly/3OJgYzi
Linkedin:   / 5312453  
Twitter:   / labiotech_eu  
Facebook:   / labiotech.eu  
Instagram:   / labiotech.eu  

About Labiotech.eu:
Labiotech.eu is an online publication covering the global biotech industry, with a mix of news and in-depth analysis. Updated daily, the site also includes a weekly podcast.

#biotech #covid19 #respiratorydisease #antivirals #antimicrobialresistance #rnaviral